Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice-Reference-Cited by-同舟云学术

Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice

Published:2015-07-04 Issue:1 Volume:3 Page:
ISSN:2051-5960
Container-title:Acta Neuropathologica Communications
language:en
Short-container-title:acta neuropathol commun

Author:

Balakrishnan Karthikeyan,Rijal Upadhaya Ajeet,Steinmetz Julia,Reichwald Julia,Abramowski Dorothee,Fändrich Marcus,Kumar Sathish,Yamaguchi Haruyasu,Walter Jochen,Staufenbiel Matthias,Thal Dietmar Rudolf

Funder

Deutsche Forschungsgemeinschaft

Alzheimer Forschung Initiative

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Clinical Neurology,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1186/s40478-015-0217-z.pdf

Reference63 articles.

1. Glenner GG, Wong CW (1984) Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120(3):885–90

2. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82(12):4245–9

3. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8):916–9

4. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740):173–7

5. Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE (2006) Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest 116(1):193–201

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Passive Anti-Amyloid Beta Immunotherapies in Alzheimer’s Disease: From Mechanisms to Therapeutic Impact;Biomedicines;2024-05-15

2. Neurobehavioral Testing as Cognitive Function Evaluation tool in Experimentally Induced Neurodegeneration in Mice;Annals of Clinical and Experimental Neurology;2024-01-05

3. Whole‐brain microscopy reveals distinct temporal and spatial efficacy of anti‐Aβ therapies;EMBO Molecular Medicine;2022-11-16

4. The Hidden Role of Non-Canonical Amyloid β Isoforms in Alzheimer’s Disease;Cells;2022-10-29

5. Syndecan-3 as a Novel Biomarker in Alzheimer’s Disease;International Journal of Molecular Sciences;2022-03-21